<p>安进（NASDAQ:AMGN - 获取免费报告）在周一发布给投资者的报告中，被华尔街 Zen 的股票研究人员将评级从 “买入” 上调至 “强力买入”。</p>
<ul>
<li>5 个医疗保健公司值得关注，因为行业轮动正在全面展开</li>
</ul>
<p>其他分析师最近也对该股票发布了报告。摩根士丹利在周五的研究报告中将安进的目标股价从 329.00 美元下调至 304.00 美元，并对该公司给予 “持平” 评级。高盛集团在 11 月 25 日的研究报告中重申了对安进的 “买入” 评级。花旗集团在 9 月 24 日的报告中将安进的目标股价从 310.00 美元上调至 315.00 美元，并给予该公司 “中性” 评级。汇丰银行在周三的报告中重申了 “买入” 评级，并对安进的目标股价设定为 425.00 美元。最后，Truist Financial 在 11 月 24 日的研究报告中开始覆盖安进的股票。他们对该股票设定了 “持有” 评级和 318.00 美元的目标价。一位研究分析师对该股票给予了强力买入评级，十位给予了买入评级，十位给予了持有评级，还有一位给予了卖出评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，共识目标价为 332.85 美元。</p>
<p><strong>查看我们关于 AMGN 的最新报告</strong></p>
<h2>安进股票上涨 0.1%</h2>
<ul>
<li>安进股票：在盈利超预期后，新的历史高点即将到来</li>
</ul>
<p>安进在周一的开盘价为 317.74 美元。安进的 1 年最低价为 253.30 美元，1 年最高价为 346.38 美元。该公司的 50 日移动平均价格为 316.12 美元，200 日移动平均价格为 298.92 美元。公司的债务与股本比率为 5.45，速动比率为 0.99，流动比率为 1.28。公司的市值为 1711 亿美元，市盈率为 24.55，市盈增长比率为 2.87，贝塔值为 0.45。</p>
<p>安进（NASDAQ:AMGN - 获取免费报告）最后一次公布季度财报是在 11 月 4 日。该医疗研究公司报告的每股收益为 5.64 美元，超出分析师的共识预期 5.01 美元，超出幅度为 0.63 美元。安进的净利润率为 19.47%，股本回报率为 162.59%。该公司在本季度的收入为 95.6 亿美元，而分析师的预期为 89.8 亿美元。在去年同期，该公司每股收益为 5.58 美元。与去年同期相比，安进的收入增长了 12.4%。安进已将其 2025 财年的指导目标设定为 20.600-21.400 每股收益。卖方分析师预计安进在当前年度的每股收益将达到 20.62 美元。</p>
<h2>安进的内部买卖情况</h2>
<ul>
<li>皇家制药如何在没有生物技术最大风险的情况下创造现金</li>
</ul>
<p>在其他新闻中，高级副总裁南希·A·格里吉尔在 11 月 20 日的交易中出售了 3,139 股该股票。股票以平均价格 337.26 美元出售，总交易额为 1,058,659.14 美元。交易后，该高级副总裁持有该公司 7,225 股股票，价值约为 2,436,703.50 美元。这笔交易代表了他们持有股票的 30.29% 的减少。该销售在向 SEC 提交的文件中披露，可以通过此超链接访问。此外，执行副总裁穆尔多·戈登在 11 月 12 日的交易中出售了 6,879 股安进股票。该股票以平均价格 336.83 美元出售，总价值为 2,317,053.57 美元。交易完成后，该执行副总裁持有该公司 41,923 股股票，价值为 14,120,924.09 美元。这笔交易代表了他们持有股票的 14.10% 的减少。该销售的披露在 SEC 文件中可用。在过去的九十天里，内部人士已出售价值 3,674,966 美元的 10,908 股公司股票。0.69% 的股票由内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>几家对冲基金最近对其在安进的持仓进行了调整。West Family Investments Inc.在第三季度将其在安进的持仓增加了 1.1%。West Family Investments Inc.现在拥有该医疗研究公司 2,760 股股票，价值 779,000 美元，在此期间又购买了 30 股。Viawealth LLC 在第三季度将其在安进的持仓增加了 0.4%。Viawealth LLC 现在拥有该医疗研究公司 7,168 股股票，价值 2,023,000 美元，在此期间又购买了 30 股。LOM 资产管理有限公司在第三季度将其在安进的持仓增加了 1.2%。LOM 资产管理有限公司现在拥有该医疗研究公司 2,554 股股票，价值 721,000 美元，在上个季度又购买了 30 股。Sittner &amp; Nelson LLC 在第三季度将其在安进的持仓增加了 0.4%。Sittner &amp; Nelson LLC 现在拥有该医疗研究公司 7,276 股股票，价值 2,053,000 美元，在此期间又购买了 30 股。最后，TAGStone Capital Inc.在第三季度将其在安进的持仓增加了 0.8%。TAGStone Capital Inc.现在拥有该医疗研究公司 4,101 股股票，价值 1,157,000 美元，在上个季度又购买了 32 股。机构投资者和对冲基金持有该公司 76.50% 的股票。</p>
<h2>安进公司简介</h2>
<p>（获取免费报告）</p>
<p>安进公司在全球范围内发现、开发、生产和交付人类治疗药物。该公司的主要产品包括用于治疗斑块型银屑病、类风湿性关节炎和银屑病关节炎的恩利昔（Enbrel）；用于治疗成人斑块型银屑病、银屑病关节炎和与贝赫切特病相关的口腔溃疡的 Otezla；用于治疗绝经后女性骨质疏松症的 Prolia；用于预防骨骼相关事件的 XGEVA；可降低心肌梗死、中风和冠状动脉再血管化风险的 Repatha；用于治疗免疫性血小板减少症患者的 Nplate；用于治疗复发性或难治性多发性骨髓瘤患者的 KYPROLIS；用于治疗红细胞数量低于正常水平和贫血的 Aranesp；用于治疗绝经后男性和女性骨质疏松症的 EVENITY；用于治疗野生型 RAS 转移性结直肠癌患者的 Vectibix；用于治疗急性淋巴细胞白血病患者的 BLINCYTO；用于治疗甲状腺眼病的 TEPEZZA；以及用于治疗慢性难治性痛风的 KRYSTEXXA。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过安进</li>
<li>高飞者：2022 年 3 月的 3 只天然气股票</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入了游戏</li>
<li>什么是股息之王？</li>
<li>3 只在 10 年期国债利率上升时值得购买的金融股票</li>
<li>即将到来的 IPO 股票锁定期，解读</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在安进吗？</h2>
<p>在你考虑安进之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而安进并不在名单上。</p>
<p>虽然安进目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

安进

<p>华尔街禅将安进的股票评级从 “买入” 上调至 “强力买入”。其他分析师的评级则各有不同，摩根士丹利下调了其目标价，而花旗集团则上调了目标价。安进的股票开盘价为 317.74 美元，市值为 1711 亿美元。近期披露了内部人士的股票出售情况，机构投资者也调整了他们的持仓。安进报告了强劲的季度收益，超出预期，并将 2025 财年的每股收益指引设定在 20.600-21.400 美元之间</p>

<p>Amgen (NASDAQ:AMGN - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a note issued to investors on Monday.</p>
<div class="lb-trans"><p>安进（NASDAQ:AMGN - 获取免费报告）在周一发布给投资者的报告中，被华尔街 Zen 的股票研究人员将评级从 “买入” 上调至 “强力买入”。</p>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 个医疗保健公司值得关注，因为行业轮动正在全面展开</li>
</ul>
</div><p>Other analysts have also recently issued reports about the stock. Morgan Stanley decreased their price target on shares of Amgen from $329.00 to $304.00 and set an &#34;equal weight&#34; rating for the company in a research report on Friday. The Goldman Sachs Group reiterated a &#34;buy&#34; rating on shares of Amgen in a research note on Tuesday, November 25th. Citigroup raised their target price on Amgen from $310.00 to $315.00 and gave the company a &#34;neutral&#34; rating in a report on Wednesday, September 24th. HSBC restated a &#34;buy&#34; rating and issued a $425.00 price target on shares of Amgen in a report on Wednesday. Finally, Truist Financial began coverage on shares of Amgen in a research note on Monday, November 24th. They set a &#34;hold&#34; rating and a $318.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $332.85.</p>
<div class="lb-trans"><p>其他分析师最近也对该股票发布了报告。摩根士丹利在周五的研究报告中将安进的目标股价从 329.00 美元下调至 304.00 美元，并对该公司给予 “持平” 评级。高盛集团在 11 月 25 日的研究报告中重申了对安进的 “买入” 评级。花旗集团在 9 月 24 日的报告中将安进的目标股价从 310.00 美元上调至 315.00 美元，并给予该公司 “中性” 评级。汇丰银行在周三的报告中重申了 “买入” 评级，并对安进的目标股价设定为 425.00 美元。最后，Truist Financial 在 11 月 24 日的研究报告中开始覆盖安进的股票。他们对该股票设定了 “持有” 评级和 318.00 美元的目标价。一位研究分析师对该股票给予了强力买入评级，十位给予了买入评级，十位给予了持有评级，还有一位给予了卖出评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，共识目标价为 332.85 美元。</p>
</div><p><strong>Check Out Our Latest Report on AMGN</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 AMGN 的最新报告</strong></p>
</div><h2>Amgen Stock Up 0.1%</h2>
<div class="lb-trans"><h2>安进股票上涨 0.1%</h2>
</div><ul>
<li>Amgen Stock: New All-Time Highs Ahead After Earnings Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>安进股票：在盈利超预期后，新的历史高点即将到来</li>
</ul>
</div><p>AMGN opened at $317.74 on Monday. Amgen has a 1 year low of $253.30 and a 1 year high of $346.38. The firm has a 50 day moving average price of $316.12 and a 200 day moving average price of $298.92. The company has a debt-to-equity ratio of 5.45, a quick ratio of 0.99 and a current ratio of 1.28. The company has a market cap of $171.10 billion, a PE ratio of 24.55, a price-to-earnings-growth ratio of 2.87 and a beta of 0.45.</p>
<div class="lb-trans"><p>安进在周一的开盘价为 317.74 美元。安进的 1 年最低价为 253.30 美元，1 年最高价为 346.38 美元。该公司的 50 日移动平均价格为 316.12 美元，200 日移动平均价格为 298.92 美元。公司的债务与股本比率为 5.45，速动比率为 0.99，流动比率为 1.28。公司的市值为 1711 亿美元，市盈率为 24.55，市盈增长比率为 2.87，贝塔值为 0.45。</p>
</div><p>Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating analysts' consensus estimates of $5.01 by $0.63. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The firm had revenue of $9.56 billion for the quarter, compared to analysts' expectations of $8.98 billion. During the same period in the previous year, the company posted $5.58 earnings per share. Amgen's revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Sell-side analysts expect that Amgen will post 20.62 earnings per share for the current year.</p>
<div class="lb-trans"><p>安进（NASDAQ:AMGN - 获取免费报告）最后一次公布季度财报是在 11 月 4 日。该医疗研究公司报告的每股收益为 5.64 美元，超出分析师的共识预期 5.01 美元，超出幅度为 0.63 美元。安进的净利润率为 19.47%，股本回报率为 162.59%。该公司在本季度的收入为 95.6 亿美元，而分析师的预期为 89.8 亿美元。在去年同期，该公司每股收益为 5.58 美元。与去年同期相比，安进的收入增长了 12.4%。安进已将其 2025 财年的指导目标设定为 20.600-21.400 每股收益。卖方分析师预计安进在当前年度的每股收益将达到 20.62 美元。</p>
</div><h2>Insider Buying and Selling at Amgen</h2>
<div class="lb-trans"><h2>安进的内部买卖情况</h2>
</div><ul>
<li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li>
</ul>
<div class="lb-trans"><ul>
<li>皇家制药如何在没有生物技术最大风险的情况下创造现金</li>
</ul>
</div><p>In other news, SVP Nancy A. Grygiel sold 3,139 shares of the stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the transaction, the senior vice president owned 7,225 shares of the company's stock, valued at approximately $2,436,703.50. This trade represents a 30.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Murdo Gordon sold 6,879 shares of Amgen stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the transaction, the executive vice president owned 41,923 shares of the company's stock, valued at $14,120,924.09. This trade represents a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 10,908 shares of company stock worth $3,674,966 in the last ninety days. 0.69% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他新闻中，高级副总裁南希·A·格里吉尔在 11 月 20 日的交易中出售了 3,139 股该股票。股票以平均价格 337.26 美元出售，总交易额为 1,058,659.14 美元。交易后，该高级副总裁持有该公司 7,225 股股票，价值约为 2,436,703.50 美元。这笔交易代表了他们持有股票的 30.29% 的减少。该销售在向 SEC 提交的文件中披露，可以通过此超链接访问。此外，执行副总裁穆尔多·戈登在 11 月 12 日的交易中出售了 6,879 股安进股票。该股票以平均价格 336.83 美元出售，总价值为 2,317,053.57 美元。交易完成后，该执行副总裁持有该公司 41,923 股股票，价值为 14,120,924.09 美元。这笔交易代表了他们持有股票的 14.10% 的减少。该销售的披露在 SEC 文件中可用。在过去的九十天里，内部人士已出售价值 3,674,966 美元的 10,908 股公司股票。0.69% 的股票由内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several hedge funds have recently made changes to their positions in AMGN. West Family Investments Inc. boosted its holdings in Amgen by 1.1% in the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company's stock worth $779,000 after purchasing an additional 30 shares during the period. Viawealth LLC raised its holdings in shares of Amgen by 0.4% during the third quarter. Viawealth LLC now owns 7,168 shares of the medical research company's stock worth $2,023,000 after purchasing an additional 30 shares during the period. LOM Asset Management Ltd lifted its position in shares of Amgen by 1.2% in the 3rd quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company's stock worth $721,000 after buying an additional 30 shares during the last quarter. Sittner &amp; Nelson LLC boosted its holdings in shares of Amgen by 0.4% in the 3rd quarter. Sittner &amp; Nelson LLC now owns 7,276 shares of the medical research company's stock valued at $2,053,000 after buying an additional 30 shares during the period. Finally, TAGStone Capital Inc. grew its position in shares of Amgen by 0.8% during the 3rd quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company's stock valued at $1,157,000 after buying an additional 32 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金最近对其在安进的持仓进行了调整。West Family Investments Inc.在第三季度将其在安进的持仓增加了 1.1%。West Family Investments Inc.现在拥有该医疗研究公司 2,760 股股票，价值 779,000 美元，在此期间又购买了 30 股。Viawealth LLC 在第三季度将其在安进的持仓增加了 0.4%。Viawealth LLC 现在拥有该医疗研究公司 7,168 股股票，价值 2,023,000 美元，在此期间又购买了 30 股。LOM 资产管理有限公司在第三季度将其在安进的持仓增加了 1.2%。LOM 资产管理有限公司现在拥有该医疗研究公司 2,554 股股票，价值 721,000 美元，在上个季度又购买了 30 股。Sittner &amp; Nelson LLC 在第三季度将其在安进的持仓增加了 0.4%。Sittner &amp; Nelson LLC 现在拥有该医疗研究公司 7,276 股股票，价值 2,053,000 美元，在此期间又购买了 30 股。最后，TAGStone Capital Inc.在第三季度将其在安进的持仓增加了 0.8%。TAGStone Capital Inc.现在拥有该医疗研究公司 4,101 股股票，价值 1,157,000 美元，在上个季度又购买了 32 股。机构投资者和对冲基金持有该公司 76.50% 的股票。</p>
</div><h2>Amgen Company Profile</h2>
<div class="lb-trans"><h2>安进公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.</p>
<div class="lb-trans"><p>安进公司在全球范围内发现、开发、生产和交付人类治疗药物。该公司的主要产品包括用于治疗斑块型银屑病、类风湿性关节炎和银屑病关节炎的恩利昔（Enbrel）；用于治疗成人斑块型银屑病、银屑病关节炎和与贝赫切特病相关的口腔溃疡的 Otezla；用于治疗绝经后女性骨质疏松症的 Prolia；用于预防骨骼相关事件的 XGEVA；可降低心肌梗死、中风和冠状动脉再血管化风险的 Repatha；用于治疗免疫性血小板减少症患者的 Nplate；用于治疗复发性或难治性多发性骨髓瘤患者的 KYPROLIS；用于治疗红细胞数量低于正常水平和贫血的 Aranesp；用于治疗绝经后男性和女性骨质疏松症的 EVENITY；用于治疗野生型 RAS 转移性结直肠癌患者的 Vectibix；用于治疗急性淋巴细胞白血病患者的 BLINCYTO；用于治疗甲状腺眼病的 TEPEZZA；以及用于治疗慢性难治性痛风的 KRYSTEXXA。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Amgen</li>
<li>High Flyers: 3 Natural Gas Stocks for March 2022</li>
<li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li>
<li>What is a Dividend King?</li>
<li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li>
<li>Upcoming IPO Stock Lockup Period, Explained</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过安进</li>
<li>高飞者：2022 年 3 月的 3 只天然气股票</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入了游戏</li>
<li>什么是股息之王？</li>
<li>3 只在 10 年期国债利率上升时值得购买的金融股票</li>
<li>即将到来的 IPO 股票锁定期，解读</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=AMGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Amgen Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在安进吗？</h2>
</div><p>Before you consider Amgen, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑安进之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而安进并不在名单上。</p>
</div><p>While Amgen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然安进目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

安进（NASDAQ:AMGN）在 Wall Street Zen 被升级为 “强力买入” 评级